BR100 Increased By (0.05%)
BR30 Decreased By (-0.02%)
KSE100 Increased By (0.53%)
KSE30 Increased By (0.58%)
BECO 6.15 Increased By ▲ 0.38 (6.59%)
BML 52.91 Decreased By ▼ -0.09 (-0.17%)
BOP 34.30 Increased By ▲ 0.31 (0.91%)
CNERGY 8.20 Increased By ▲ 0.09 (1.11%)
DCL 12.36 Increased By ▲ 0.16 (1.31%)
FCCL 53.60 Increased By ▲ 0.77 (1.46%)
FCSC 5.30 Increased By ▲ 0.23 (4.54%)
FFL 18.10 Increased By ▲ 0.15 (0.84%)
FNEL 1.32 Increased By ▲ 0.03 (2.33%)
HUMNL 10.98 Increased By ▲ 0.10 (0.92%)
KEL 8.07 Increased By ▲ 0.05 (0.62%)
KOSM 5.52 No Change ▼ 0.00 (0%)
MLCF 87.50 Increased By ▲ 0.99 (1.14%)
NBP 186.49 Increased By ▲ 1.33 (0.72%)
PACE 10.72 Increased By ▲ 0.14 (1.32%)
PAEL 39.60 Increased By ▲ 0.18 (0.46%)
PIAHCLA 26.35 Increased By ▲ 0.13 (0.5%)
PIBTL 16.76 Increased By ▲ 0.09 (0.54%)
PPL 229.63 Increased By ▲ 1.45 (0.64%)
PRL 34.87 Increased By ▲ 0.19 (0.55%)
PTC 65.70 Increased By ▲ 0.37 (0.57%)
SEARL 90.44 Increased By ▲ 0.31 (0.34%)
SSGC 26.94 Increased By ▲ 0.34 (1.28%)
TELE 8.38 Increased By ▲ 0.10 (1.21%)
THCCL 59.19 Increased By ▲ 0.69 (1.18%)
TPLP 8.35 Increased By ▲ 0.13 (1.58%)
TREET 24.69 Increased By ▲ 0.16 (0.65%)
TRG 70.13 Increased By ▲ 0.42 (0.6%)
WAVES 9.95 Increased By ▲ 0.01 (0.1%)
WTL 1.28 No Change ▼ 0.00 (0%)
اردو
Android App
Print Edition Dollar to PKR
Budget 2026-27 Iran-US war Petrol Prices Gold Rates Podcasts PSX Notices
World

German court suspends mRNA patent trial against BioNTech

Published September 28, 2023 Updated September 28, 2023 03:04pm
Save
1 min
comment
By Reuters
Add BRecorder as a trusted
source on Google
Google Preferred Source

DUESSELDORF: A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its US partner Pfizer.

The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending a decision by the federal patent court on a lawsuit filed by BioNTech.

Germany’s Scholz ‘not convinced’ about tariffs on Chinese EVs

It had asked the higher court to review the validity of CureVac’s intellectual property rights. A decision is expected in December.

Germany BioNTech Pfizer CureVac Covid 19 vaccine German court

Comments

Comments are closed for this article.

More Stories

Browse all stories